Systematic study of the six cysteines of the E1 subunit of the pyruvate dehydrogenase multienzyme complex from Escherichia coli: none is essential for activity.
Variants of the Escherichia coli 1-lip pyruvate dehydrogenase multienzyme complex (1-lip PDHc) with the C259N and C259S substitutions in the putative thiamin diphosphate-(ThDP-) binding motif of the pyruvate dehydrogenase component (E1, EC 1.2.4.1) were characterized. Single substitutions were made at the five remaining cysteines of the E1 component, creating the C120A, C575A, C610A, C654A, and C770S variants to test the hypothesis that the activity loss that accompanies exposure of the enzyme to fluoropyruvate, bromopyruvate, and 2-oxo-3-butynoic acid is the result of the modification of approximately one cysteine residue per E1 monomer. Surprisingly, all single cysteine E1 variants could be reconstituted with E2-E3 subcomplex and showed PDHc activity ranging from 74% to 96% that of the parental enzyme. The specific activities of C259N and C259S variants of 1-lip PDHc were 58% and 27% relative to that of the parental 1-lip PDHc. All five single cysteine E1 variants, along with the C259N and C259S variants of 1-lip PDHc, could also (1) be inactivated with fluoropyruvate and 2-oxo-3-butynoic acid, (2) were subject to inactivation by the monoclonal antibody 18A9 reported from one of our laboratories, and (3) were subject to regulation by pyruvate and acetyl-CoA. It was therefore concluded that none of the six cysteine residues is essential for the activity of the E1 component or of the complex. When tested with the putative transition-state analogue, thiamin 2-thiothiazolone diphosphate, all but the C259S and C259N variants were very potently inhibited, the stoichiometry for parental E1 being about 1.6 mol of inhibitor/mol of E1 subunit. The C259S and C259N E1 variants required at least 25-fold greater inhibitor concentration to achieve the same level of inhibition. C259 is located in the putative thiamin diphosphate-binding motif of the enzyme [more exactly, it is adjacent to a ligand to the Mg(II) ion]. It is therefore concluded that thiamin 2-thiothiazolone diphosphate is not a transition-state analogue; rather, it is a potent inhibitor of the complex because of a specific interaction with the C259 residue.
Nemeria
N
N
Department of Chemistry, Rutgers, State University of New Jersey, Newark 07102, USA.
Volkov
A
A
Brown
A
A
Yi
J
J
Zipper
L
L
Guest
J R
JR
Jordan
F
F
D000105:Acetyl Coenzyme A / Q000378:metabolism; D001667:Binding, Competitive; D003545:Cysteine / Q000235:genetics / Q000378:metabolism*; D019281:Dimerization; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D004926:Escherichia coli / Q000201:enzymology* / Q000235:genetics; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D005246:Feedback; D014644:Genetic Variation; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D010957:Plasmids / Q000138:chemical synthesis; D011768:Pyruvate Dehydrogenase Complex / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011773:Pyruvates / Q000494:pharmacology; D013835:Thiamine Pyrophosphate / Q000031:analogs & derivatives / Q000494:pharmacology
D005231:Fatty Acids, Unsaturated; D011768:Pyruvate Dehydrogenase Complex; D011773:Pyruvates; C017319:3-fluoropyruvate; C037086:2-keto-3-butynoic acid; C033041:thiamine thiothiazolone pyrophosphate; D000105:Acetyl Coenzyme A; D003545:Cysteine; D013835:Thiamine Pyrophosphate